Overview

• Bayer CEO Bill Anderson announced during the company's virtual annual meeting that ongoing litigation could force the cessation of glyphosate sales in the United States.
• The company is currently managing approximately 180,000 glyphosate-related cases globally, with 67,000 still unresolved as of January 2025.
• Bayer has already paid $11 billion in settlements related to glyphosate lawsuits, with potential liabilities hinging on a US Supreme Court decision expected by mid-2026.
• To strengthen its financial position, Bayer has requested shareholder approval for a capital increase of up to 35%, citing the need to prepare for future legal costs.
• Despite restructuring efforts that have cut management layers and saved €500 million, Bayer faces challenges in both its agricultural innovation pipeline and pharmaceutical development.